MedTrace Logo

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

NCT03014102 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether recombinant human thrombopoietin are effective in peripheral blood progenitor cells mobilization for autologous transplantation.

Conditions

  • Thrombocytopoietin
  • Hematopoietic Stem Cell Mobilization
  • Hematopoietic Stem Cell Transplantation

Interventions

DRUG

Recombinant Human Thrombopoietin

Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.

Sponsors & Collaborators

  • Hongnan Mo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03014102 on ClinicalTrials.gov